icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
T9SuQcUL5yTgU7r0